       Document 0561
 DOCN  M9630561
 TI    Cost-effectiveness: from whose perspective?
 DT    9603
 AU    Hillman AL; School of Medicine, University of Pennsylvania,
       Philadelphia,; USA.
 SO    J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 4:S14-8.
       Unique Identifier : AIDSLINE MED/96075584
 AB    Evaluating the cost-effectiveness of medical interventions, particularly
       pharmaceuticals, has been the focus of much debate in this country over
       the past few years. Although the support for efficient utilization of
       monies is widespread, the delicate balance between optimizing patient
       outcome with the costs to do so in high-risk patients is especially
       difficult. Although research in the field of cost-effectiveness is
       widespread, at present there are few guidelines in this country.
       Furthermore, the introduction of bias is a serious concern in the
       interpretation and validation of studies, often limiting their utility.
       Guidelines that can be implemented to minimize bias in economic research
       have been identified to include administrative, methodology-based, and
       ethical parameters. The standardization and implementation of such
       guidelines can reduce bias in economic research and optimize study
       validity. This review focuses on these issues and suggests that initial
       steps to produce unbiased economic research include total disclosure,
       appropriate comparator selection, complete release of all relevant data,
       and the cooperation of all involved parties.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY/ECONOMICS  Antiviral
       Agents/ECONOMICS  Cost-Benefit Analysis/*TRENDS  Economics,
       Medical/STANDARDS  Ethics, Professional  Guidelines  Human
       Research/STANDARDS  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

